Compare GTN & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTN | MRVI |
|---|---|---|
| Founded | 1897 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 452.2M | 472.8M |
| IPO Year | N/A | 2020 |
| Metric | GTN | MRVI |
|---|---|---|
| Price | $5.26 | $3.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $8.50 | $4.57 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $13.44 | $11.80 |
| Revenue Next Year | N/A | $7.74 |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.13 | $1.67 |
| 52 Week High | $6.31 | $4.11 |
| Indicator | GTN | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 52.07 |
| Support Level | $4.42 | $3.25 |
| Resistance Level | $5.35 | $3.65 |
| Average True Range (ATR) | 0.39 | 0.19 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 50.17 | 58.74 |
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.